MichaelRCharltonMD

Summary

• I am a physician scientist who is American Board of Internal Medicine certified in Gastroenterology and Hepatology and Transplant Hepatology. I attained the rank of Professor of Medicine at Mayo Clinic, where I served as Chief of Hepatology and Medical Director of Liver Transplantation. I subsequently served as Director of Transplantation and Regenerative Medicine at Intermountain Healthcare. I am currently Chief of Hepatology and Medical Director of the Transplant Institute at the University of Chicago. I received training in basic and translational research methods through the NIH GCRC-based CAP program and have been principal investigator on multiple NIH grants, including as principal investigator on an RO1. I have also served as lead and principal investigator in many clinical trials sponsored by NIH and industry. I was selected to serve on a multisociety panel of experts to develop a widely utilized set of guidelines for the management of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH) and also for hepatitis C infection, directing two sections. I am past -president of International Liver Transplant Society. My translational research has focused on HCV and NAFLD/NASH. My basic research has consistently focused on NAFLD, building on early NIH-sponsored career training grant in the Mayo Clinic Center for Clinical and Translational Science (CCaTS) and in the Mayo Clinic Endocrine Research Unit, experiences that have proved invaluable in studying fatty liver disease. My current basic research focus is on the role of the microbiome in dietary-induced fibrosing NASH, in experiments that utilize the animal model developed in my lab. This work is being conducted in the University of Chicago’s Duchossois Family Institute, an internationally renowned center devoted to the study of the microbiome. I also continue translational studies and publications utilizing national databases.